A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents With Irritant (Non-Allergic) Rhinitis
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2016
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Rhinitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 23 Mar 2010 New trial record.
- 02 Mar 2010 Results were presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.